Formulary Status % of Lives # of Plans
Preferred 4% 138
Covered 21% 2248
Restricted 43% 1396
Not Covered 32% 3212
Can anyone verify whether European, MEA Aug 3 Time Mag has Afrezza Ads? " Game of Thrones"
Sanofi launches DTC campaign for Afrezza
July 30, 2015
Sanofi launches DTC campaign for Afrezza
The DTC campaign for Afrezza launched this week.
Sanofi this week launched “Surprise, it's insulin,” the first direct-to-consumer campaign for its inhaled insulin product, Afrezza, as the drugmaker seeks to boost sales after the disappointing launch of the new therapy.
The ads, now appearing on www.afrezzaDOTcom, feature three people casually using the inhaled insulin in public spaces, like a table at a restaurant or before eating a sandwich on a hike in the woods. A print ad in the Aug. 3 issue of Time magazine mimics the online video spots.
Afrezza is a mealtime insulin and it's also the only inhaled insulin on the market. MannKind's bet in developing and marketing Afrezza is that some diabetes patients would prefer to use an inhaled insulin rather than using needles and pens every day.
Other digital components of the campaign, which was developed by Havas Health, are also being rolled out. A Sanofi spokeswoman declined to provide additional information about the campaign, including spend.
Sanofi is the marketing partner for Afrezza, which was developed by biopharma firm MannKind. Sanofi said Thursday that the insulin generated about $2.2 million in sales in the second quarter, bringing total sales since the launch in February to $3.3 million. Analysts had predicted that the therapy would be a blockbuster but have since cut sales forecasts for Afrezza.
“MannKind investors need to consider the possibility that the company may never even come close to profitability even with an FDA-approved drug for diabetes,” Maxim Jacobs, analyst at Edison Investment Research, said in a note on Thursday.
The companies have grappled with specific challenges to marketing an inhaled insulin product: It's the only one available in the US since Pfizer pulled its marketing support in 2007 for Exubera over weak sales; the FDA label requires that patients taking Afrezza undergo regu
Danbury manufacturer Mannkind triples production despite slow sales of Afrezza
By Dirk Perrefort | August 1, 2015
The annual stockholders meeting for Mannkind Corporation which recently gained approval from the FDA for a new form of insulin. On Thursday May 21, 2015, in Danbury, Conn. Photo: H John Voorhees III / H John Voorhees III / The News-Times
Photo: H John Voorhees III / H John Voorhees III
Image 1 of 2
The annual stockholders meeting for Mannkind Corporation which recently gained approval from the FDA for a new form of insulin. On Thursday May 21, 2015, in Danbury, Conn.
Image 1 of 2
The annual stockholders meeting for Mannkind Corporation which recently gained approval from the FDA for a new form of insulin. On Thursday May 21, 2015, in Danbury, Conn.
DANBURY — Shares of Mannkind fell more than 13 percent this week after its marketing partner announced lackluster sales of Afrezza, an inhaled form of insulin that executives believe will revolutionize the treatment of diabetes.
In a reporting earlier this week, Mannkind’s marketing partner for the drug, Sanofi, announced that sales during quarter that ended on June 30 amounted to $2.2 million. Afrezza was approved by the U.S. Food and Drug Administration last year and the company began offering it for sale in February. Total sales for the drug since its release five months ago were reported at $3.3 million.
Despite the slow start, company officials announced in a statement Friday that they will be tripling the production of the drug at its Danbury facility by opening two additional filling lines.
“With the completion of the validation effort, which began last quarter, we can support a demand of more than 300 million cartridges per year,” Hakan Edstrom, the president and CEO of MannKind, said in the statement. “The addition of the 12 unit cartridge will provide patients with another option to receive their prescribed dose.”
While sales of the drug been slow, users of the drug have continued to be their biggest supporter. Unlike some insulins that have to be taken well before a meal, Afrezza can be taken immediately before mealtime and quickly leaves the body, allowing for consistent blood sugar levels in patients who use the drug. Many users have taken to Twitter and other social media outlets to praise the drug.
“Why isn’t every person with #diabetes asking their doctor about #Afrezza?” tweeted Twitter user Laura Kronen earlier this week. “My life has transformed since taking it. It’s truly amazing.”
During the company’s shareholder meeting in the spring, shareholders who continue to be bullish on the drug, many of whom where diabetic patients themselves or related to one, questioned the efforts, or the lack thereof, by Sanofi to bring the drug more attention in the market.
“When is the CEO of Sanofi going to stand up and start promoting Afrezza?” Ken Poli, one of the many investors who attended the meeting, said at the time.
Investors at the meeting also expressed concerns about the significant short position in the stock and raised allegations of stock manipulation by some of the analysts who have been downgrading and openly bashing the company.
“I’m not going to name names, but these are people with an agenda who are spreading lies about the company, and nobody is challenging them,” Michael Moss said during the annual meeting.
Matt Pfeffer, the company’s chief financial officer, has said company executives are equally frustrated by the attacks against the company, adding that those who respond to such attacks are usually fighting a losing battle. Pfeffer was not available for comment Friday.
Shares of Mannkind started the week at about $5 per share, but declined to around $4.32 per share on Friday, a decline of 13.6 percent.
Is the Inhaled-Insulin Afrezza the Real Deal?
By Alexander Wolf and Sally Kim
After the rapid-acting inhaled insulin Afrezza launched this February, we have been very eager to learn more about how this new product impacts patients’ day-to-day diabetes management. We recently spoke with Ana Ortiz (a type 1 patient) and Bill Kinder (a type 2 patient), two Afrezza users with very different backgrounds. Ana and Bill were both involved in clinical trials of Afrezza and volunteered at its official launch event. You can see our Q&A below, but for a quick refresher on Afrezza:
Afrezza comes in two cartridge sizes right now, equivalent to four units and eight units of inject rapid-acting insulin. It was recently announced that a 12-unit cartridge would become available in late 2015, for anyone who may require larger doses of insulin.
The small inhaler device is usable for 15-days, after which it should be replaced with a new inhaler.
Afrezza peaks in just 12-15 minutes, making it much faster than current rapid-acting insulins (Humalog, Novolog, and Apidra) that generally take about 45-90 minutes to peak.
Afrezza does have minor respiratory side effects – in its phase 3 clinical trials, 20-30% of those on Afrezza experienced a cough, compared to none of the participants on Novolog. So before starting on Afrezza, a lung function test (spirometry) is required. Patients also can’t use Afrezza if they have chronic lung problems, such as asthma or COPD.
Given the dosing size, Afrezza may be best suited for: patients with type 2 diabetes, an ultra-fast correction dose in type 1 patients, or for very large meals.
Ana Ortiz and Bill Kinder on their Experience Using Afrezza
ALEX: Could you please briefly introduce yourselves?
BILL (T2): I have a personal connection with diabetes because I have type 2. I got involved with Afrezza through its clinical trials. I was asked if I’d be interested in a trial involving inhaled insulin, and felt like I could learn a lot about my diabetes and treatment from it. I was particularly excited about the potential of a product where you inhale instead of inject insulin. There are quite a few people, there’s even a name for us who have a fear of needles [needlephobic], so I thought it was a great idea. In the trial I learned not only that it was a great idea but also an effective product. It had beneficial effects for me in lowering my blood sugar levels. After that, I came back to Dallas and discussed with my doctor, who had no real information about it or how to prescribe it. But he’s a really good doctor, and once he gave me a prescription, I filled it, and have been using it since.
ANA (T1): I’m 28, I’m in Dallas, and I got involved with Afrezza through my doctor. Since going back on it after the clinical trials, it’s been close to a month now and I’m already noticing the effects of Afrezza and how much better it’s been able to control my diabetes. I have type 1 diabetes, so I rely on injected insulin and have had to switch between different long-acting insulins because of my insurance and other reasons. Afrezza has been a very good supplement with that. Although Lantus worked for me well, Afrezza was able to bring down my blood sugar levels. It was an adjustment getting back on it from the trial, but it was all worth it. There’s a huge payoff as opposed to injected insulin.
ALEX: While the exact value of course varies each meal, in your experience how does a 4-unit cartridge of Afrezza typically change your blood sugar levels?
BILL (T2): Since I got Afrezza in February, I started checking my blood sugar regularly and have been recording on a notepad. It’s hard to say exactly because there’s so much arithmetic between the time of day, the number of carbs eaten, and how soon before you eat you take Afrezza, but from a general point if I take it right before I eat then my levels don’t go up that high. Instead of hitting 225 mg/dl I may only jump to 145 mg/dl.
ANA (T1): It really does depend on where you start, and there’s a lot of arithmetic involved. If I had to guess, Afrezza decreases my blood glucose levels about 50 mg/dl less than where I started. Two hours post-meal it brings it down to a good level around 100 to 120 [mg/dl]. My injected insulin was nowhere near that.
ALEX: Have you seen any effects of Afrezza on hypoglycemia?
BILL (T2): I set a good lower limit of 70 mg/dl on my CGM and I’ve never had any hypoglycemic issues. I’m lower than I used to be and that’s a good thing, but it’s a little different because I’m used to having higher blood sugar.
ANA (T1): It’s definitely helped with the hyperglycemia. Sometimes I’ll have low blood sugars with Afrezza, but it’s not as extreme – it’s not in the 50’s [mg/dl] anymore. With Afrezza, the lowest I’ve seen is 68 mg/dl or somewhere in the 70s, and it’s not as frequent.
SALLY: What has surprised you guys most about using Afrezza?
BILL (T2): There were no significant surprises. I’ve been impressed at how quickly it works. If I take it at the right time then I can keep my blood sugars at a pretty normal range. My goal with Afrezza is to maintain an A1c that is a normal person’s A1c and it looks like I may be able to do that.
ANA (T2): How quickly it acts compared to my Humalog. It’s so much easier and it has fewer materials and supplies associated with it. I love that it comes in a pack of 3: breakfast, lunch and dinner. When I don’t use it for breakfast I can just throw it in my purse. And I like how fast it acts, so I can take it right before a meal. Before with Humalog, I would have to calculate doses and inject five to ten minutes before I eat. But now I can eat it with the food right in front of me.
SALLY: What’s the most challenging part of using Afrezza?
BILL (T2): My experience is a little different. I was not on a fast-acting insulin before. After the Afrezza trial, my A1c went up higher than it was when I was in the trial, which indicated to me that I wasn’t on the placebo during the trial. My doctor prescribed Lantus to me to begin trying to control my diabetes better. I did that until the Afrezza was available. Once it was, I went back and started using Afrezza. It really has helped me a lot with mealtime spikes. I’ve since gotten a continuous glucose monitor and it’s extremely easy for me. I didn’t switch from one fast-acting insulin to another – I just added Afrezza as a type 2, and only where I needed it.
ANA (T1): Adjusting to a different insulin is a little hard. Because I’m inhaling it, there’s a little bit of coughing, but it didn’t last as long this time as in clinical trials. For me, it was just the dosing and counting different carbs. Other than that it was pretty easy.
SALLY: If you could make one improvement to Afrezza what would it be?
BILL (T2): I don’t know what I would do at this point in time to correct it. I’ve found the inhaler to be extremely discreet, small, and well functioning. I don’t have any issues with it. When I first started back on Afrezza I had a small urge to cough, but I resisted because I wanted to retain the insulin. That was extremely minor, and it has essentially just disappeared.
ANA (T1): I think the inhaler. It was different from the one in the trial. We had a reusable inhaler that we cleaned and maintained. But this disposable one is smaller, and there are a certainly a lot of benefits to the one we’re using now too. The coughing is less, for example. Many of the things that were negative about it before are resolved this time around. I do wish, though, that it were something that I could reuse still and not have to get a separate prescription for the inhaler and the cartridges.
ALEX: Other than the minor coughing issues, have there been any other side effects with Afrezza?
BILL (T2): No side effects for me.
ANA (T1): Not for me other than the coughing, which was very minor.
ALEX: Do you expect to use the new 12-unit cartridge in your management?
BILL (T2): I think I can use just the 4 and 8 without much problem. You develop a habit of trying to keep your carbs under control as you manage them with the 4 and 8. There might be times, if I’m going to a wedding or a big holiday dinner, where it might be nice to have a 12. I know a gentleman also on Afrezza, and his blood sugar is so high he takes two or three 8 unit doses at a time. I know from his experience that a 12 unit dose would be very convenient. There is a need for a 12, and there could occasionally be a need for a 12 for me.
ANA (T1): Personally no, not me. I don’t eat enough and I don’t anticipate using the 12. If I’m high going into the meal and want to eat a heavier meal, then I might use the 8, but definitely not the 12.
ALEX: How would you describe the ideal person to take Afrezza?
BILL (T2): Anyone with diabetes could benefit from Afrezza. If you have high blood sugar, in my experience this is the easiest way for you to control it.
ANA (T1): Someone who eats three regular meals per day. It might not be for people on diets with smaller meals, or people who eat more meals per day. It’s do-able, but you have to figure out a routine and stick with it.
MannKind slumps after Sanofi details Afrezza sales
Shares of MannKind stumbled Thursday after the French pharmaceutical giant Sanofi detailed low initial sales for a fast-acting, inhaled insulin developed by MannKind.
Sanofi said during its second-quarter earnings report that Afrezza brought in 2 million euros ($2.2 million) in the three months that ended June 30 and 3 million euros in the first half of the year.
Sanofi licensed Afrezza's worldwide marketing rights from MannKind Corp., and the drugmakers launched the insulin in February.
Afrezza was approved by the Food and Drug Administration last year for patients with either Type 1 or 2 diabetes. The drugmakers launched the insulin hoping that it will appeal to millions of diabetes patients who dislike injecting insulin and want a fast-acting alternative.
Valencia, California-based MannKind has no other drugs on the market. In the first quarter this year, it reported a loss of $30.6 million on no revenue.
Its stock dropped 4.3 percent, or 19 cents, to $4.25 in midday trading Thursday.
Griffin Securities analyst Keith Markey said the decrease surprised him, since Afrezza's prescription numbers were widely known. He said sales have been hampered so far by a few factors, including minimal insurance coverage. But he expects that to change later this year, as coverage improves and the marketing focus shifts more toward consumers instead of mainly educating doctors.
"When you're talking about a very competitive market ... having insurance coverage is crucial," said Markey, who owns MannKind shares.
Method for treating hyperglycemia with GLP-1
Patent number: 9078866
Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with Type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
Filed: January 8, 2010
Issued: July 14, 2015
Assignee: MannKind Corporation
Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
Patent number: 9089497
Abstract: Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.
Filed: September 16, 2010
Issued: July 28, 2015
Assignee: MannKind Corporation
Inventors: Mark Hokenson, Keith A
Timothy M. Anderson - Sanford C. Bernstein & Co. LLC
I just wanted to clarify your earlier comments on the recent reorganization. Did you say that it would not necessarily lead to any cost savings? That's my first question.
Second question is on M&A. The company obviously has a long history of doing deals. Nothing substantial has happened since Genzyme a few years ago. I'm wondering how the company is viewing the landscape at the moment, along the lines of current valuations of potential targets. And is M&A potentially on hold for the company, given the recent change in leadership and also the reorganization and the need to reassess the direction of the company?
And then my last question is on biosimilar Lantus. You note on one of your slides that it has launched in two Eastern European markets. I'm wondering if you can tell us what the effective price is of the biosimilar relative to Lantus in those two markets.
Olivier Brandicourt - Chief Executive Officer
All right, Tim. Thank you for your questions. So, again, I'd like to come back to the aim of achieving this transformation first. So, I mentioned focus, simplification; it will increase speed of decision-making. During the first quarter, I insisted that we need to have single point of accountability to improve governance and that's part of the equation, overall decreasing complexity across the organization.
And because of what I mentioned about specialization, I think that should lead to engaging more deeply our customers in those different lines of businesses. And one point is to allocate resources more effectively and efficiently. So, if we do that and if we do the last one, then we should logically see some savings. That should lead to some saving that could be reinvested in the business and R&D. So, that's the answer.
The second is M&A. M&A, yeah, it's part of the tools we may use for the right opportunity. I think that's what we are saying for a little while. We have not been engaged in M&A in the last two or three years. But before that, as you underlined, Sanofi was involved in midsize like Genzyme or bolt-on acquisitions such as Merial and Chattem. And this is definitely part of what we can continue to do or start again to do. Our balance sheet is pretty strong and our debt level is low. And that would be my answer.
On the biosimilar Lantus, yes, we do have some information and Peter Guenter will give you that.
Peter Guenter - Executive VP-Global Commercial Operations
Yeah. Hi, Tim. So, as we speak, we have three countries actually in Europe. We have Czech Republic, Slovakia and Estonia where the product had been introduced and the price differential compared to the Lantus price varies between 15% and 20%, one five and 20%. What is also already known is that we expect Lilly to launch in the UK, which would be their first significant market, obviously. We expect them to launch in September and we know that the price differential there will be 15%, that is one five percent to be precise.
Six Things to Know Before Starting Afrezza
Some of you may have heard that I’ve been having issues with Afrezza, the new inhalable insulin from MannKind/Sanofi that’s such a hot commodity among investors.
I’m disappointed that it doesn’t seem to be working as well for me now as it did at the outset (I’ve been using it since mid-March), but I am in direct contact with the product team to troubleshoot, in the hopes that I can return to the amazing results I saw back in Spring.
Meanwhile, purely in the interest of helping fellow patients who may wish to try Afrezza, here are six things you may want to know before you get started:
1) Adjusting Quantity – Be aware that you will need MORE Afrezza than any other short-acting insulin. The “units” of Afrezza are by no means a one-to-one relationship to the unit measures we PWDs (people with diabetes) are used to. You may also find, like I have, that while a 4-unit dose of Afrezza packs a punch in the early days of use, as time goes on you need to increase your dosage. So think about ordering the mixed pack of Afrezza, that includes 4 and 8-unit cartridges. Otherwise, if you need higher doses, you may end up having to inhale 3 or 4 times or more per meal, which is highly inconvenient. Sanofi’s Senior Medical Director Diabetes and U.S. Medical Lead for Afrezza Anders Boss tells me the 12-unit option that’s now FDA approved may be available as early as September.
2) Inhalation Technique – Boss also reminds us that it’s important to hold the device level before inhaling, and then tilt it just a little bit down towards your chin while dosing. Do not point it upwards at all. Also be sure to take a long, deep inhalation, rather than sucking it into your mouth like you might when smoking a pipe. (And by all means don’t hold the inhaler upside-down, like I did in my initial photo mishap; although NOTE that was simply a photo opp gone bad. I NEVER used the inhaler that way, and am pretty sure it’s actually impossible to do so. Correct inhaler positioning shown below.) See also this Afrezza training video for best practices on inhalation technique. Afrezza inhaler
Also: Boss says refrigerated Afrezza should be allowed to rest at room temperature for about 10 minutes before you use it, because a too-cold cartridge can create condensation, causing the powder to clump and get stuck in the top of your mouth. (There’s one problem you never imagined having with insulin, ay?!)
3) Colds and Cough – When I caught a cold and got very phlegmy earlier this summer, I found it very difficult to dose Afrezza without coughing it out mid-inhalation. The effects of this actually lasted for several weeks after the rest of my cold symptoms were gone. I could actually see the white powder coming out my mouth or nose as I struggled to keep my cough in check while dosing.
Interestingly, Boss says that having a common cold should not interfere with Afrezza’s effectiveness. He says in studies, they’ve started patients who had a cold and compared the results to those of healthy patients, without incident. All I can tell you from personal experience as a type 1 pumper is that if you do have a cold, a little bolus boosting from your pump may be in order – especially since being sick increases your overall insulin needs. And to reduce the “cough effect,” be sure to exhale hard each time before attempting to inhale Afrezza.
4) Leftover Powder – I was also very worried about seeing some residual white powder left in the cartridge after most doses: was all the insulin really getting into me?
But Boss reassures us that a little leftover powder in a used cartridge should not cause concern. The manufacturers Afrezza cartridgedon’t expect 100% absorption, which is also the case with injected insulin, he says. “It’s OK if about 8% still seems to be in the cartridge afterwards. That’s calculated in. You lose some in the mouth, some in the cartridge. It’s such a fine powder that most of it absorbs in the lungs.” OK. Wow.
5) Two-Unit Option & Kids – Those who do continue to need small amounts of Afrezza will be happy to hear that Sanofi is actively “looking at a 2-unit option, with correction doses in mind and for kids.”
In fact, they are in the process of setting up pediatric trials now, Boss says. The first study will focus on pharmacogenetics (genetic drug response) to be sure that children will absorb inhaled insulin the same way, and whether they can handle 4-unit doses.
6) ePatients Beware – If you plan to blog, or in particular, Tweet about your experiences with Afrezza, beware investor trolls! They are mostly obvious with brand new Twitter accounts showing only an “egghead” profile pic, and a timeline that talks nothing but #Afrezza. Some are more subtle. But all are pretty ruthless in their attempts to control the message in the interest of influencing MannKind stock prices to their own advantage. I guarantee that unless you are saying 100% glowingly positive things about Afrezza all the time, you will be hounded and patronized. I encourage you to BLOCK anyone who is obviously in that camp, possibly using a new tool called Blocktogether (thx @ScottLeibrand for that tip!)
Afrezza in the Real World - DiabetesMine
We’d love to hear from any PWDs out there using Afrezza in the trenches of day-to-day diabetes. What have you learned that might be share-worthy? Please don’t be afraid to speak up.
Sales of MannKind's inhaled insulin continue slow start - LA Times
MannKind Corp.’s inhaled insulin drug Afrezza continued its slow launch in the second quarter of the year.
Sanofi, the French pharmaceutical company that’s selling Afrezza in a partnership agreement with MannKind, said it sold just $2.2 million of the drug in the quarter that ended June 30. That means that in its first five months, sales have reached just $3.3 million – a disappointing result considering some analysts expect sales to reach $1 billion a year.
MannKind’s stock was down 1 cent, or 0.2%, to $4.43 at 12:15 p.m. Pacific time. It initially fell 10%, but rebounded later in the trading session.
Matthew Pfeffer, MannKind’s chief financial officer, said he expects sales to pick up as Sanofi launches a direct-to-consumer marketing campaign. This month, Sanofi placed a three-page advertisement in Time magazine, seeking to increase consumer awareness of the new drug. It has also expanded sales staff assigned to market the drug, Pfeffer said.
“Advertising and new Internet-based marketing efforts did not begin until this quarter, so their effects have not yet been seen,” Pfeffer said in an email.
The Food and Drug Administration approval of Afrezza in June 2014, following more than a decade of research, testing and regulatory setbacks.
MannKind’s founder, 89-year-old Alfred Mann, said he expects Afrezza to become one of the top-selling drugs in U.S. history. He said its benefit goes far beyond the convenience of inhaling instead of injecting it; Afrezza is extremely fast-acting and clears the body quickly. Instead of having to plan insulin injections long before meals, users can take a quick puff of Afrezza immediately before eating.
The FDA, however, required that all patients pass a lung-function test before they can use the drug. It also ordered MannKind to include a warning that the drug should not be used by smokers or people with lung disease.
Cost is another consideration. Sanofi’s wholesale price for 20 units a day of Afrezza is $9.29, compared with $5.23 for its injected insulin, Apidra. Sanofi is offering coupons on its website to help patients cover co-pays.
To this point, the biggest marketing push has come from Afrezza users, who have used social media sites such as Twitter and Reddit to spread the word. Many users of the drug have said they are extremely happy with its effectiveness.
Analysts at Goldman Sachs are pessimistic about Afrezza’s future, rating Mannkind's stock a sell and saying in a recent report that the number of prescriptions is “far too low to reach profitability near-term.” The investment bank has lowered its sales estimate for the drug twice this year.
EBM: Can you update us on the Diabetes performance this quarter? How is the launch of Toujeo® progressing?
Olivier Brandicourt: Diabetes sales declined 3.8% during the Q2, consistent with the previous quarter and in-line with our expectations for the full year.
Diabetes sales in the U.S. decreased 14% year-over-year to just over 1.1 billion euros, mainly reflecting the continued pricing impact on Lantus®. Diabetes sales in the U.S. accounted for 57% of worldwide Diabetes sales or about 12.1% of Group sales. Importantly, sales outside the U.S. represented 43% of total Diabetes sales and increased 11.2% to 854 million euros, which offset a substantial portion of the negative pricing impact in the U.S. market.
Toujeo®, our next-generation basal insulin, was launched in the U.S. market at the end of March. Total sales of the product were about #$%$13 million in the second quarter and #$%$20 million in the first half. Importantly, we have already achieved significant market access. As of early August, 73% of lives covered by commercial plans have unrestricted access to Toujeo®, including 45% of lives with preferred Tier 2 access. In Medicare Part D, 91% of lives are covered with unrestricted access to Toujeo®. This is a very encouraging start and we are successfully defending our position in the total U.S. basal market.
Following EU approval in April, Toujeo® was launched in Germany, the Netherlands and some Nordic countries. Toujeo® was also recently approved in Japan, Canada and Australia.
SECOND QUARTER RESULTS 2015
July 30, 2015
Second Quarter Results 2015 will be presented by the management during a live audio webcast. The presentation will be followed by a Q&A session.
In order to facilitate analysts’ forecasts on Q2 results 2015, Sanofi would like to highlight the following items:
Pre-quarterly Results Communication
7:30 am CET / 1:30 am EST: Press Release
2:30 pm CET / 8:30 am EST: Live audiocast of the conference call with the financial community
Call in numbers
France: +33 (0) 1 70 77 09 47
UK: +44 (0) 203 0432 439
US: +1 866 907 5925
France: +33 (0) 1 72 00 15 01
UK: +44 (0) 203 367 9460
US: +1 877 64 230 18
Conference code: 295043#
AFREZZA GUY (@Afrezzaguy) tweeted at 11:19am - 18 Jul 15:
@MrHaigs @Cigna Cigna covered Afrezza from the very beginning they recognized a game changer and I never had any issues.
AFREZZA GUY (@Afrezzaguy) tweeted at 11:22am - 18 Jul 15:
@MrHaigs @Cigna I went through their home delivery and received a 3 month supply of #afrezza for $80 which Sanofi refunded thru card program
Cigna (@Cigna) tweeted at 1:35am - 18 Jul 15:
@Afrezzaguy Hi, thank you for the positive feedback. If there's anything I can help with, please email me at LetUsHelpU@CignaDOTcom.Thank You
AFREZZA GUY (@Afrezzaguy) tweeted at 1:52am - 18 Jul 15:
@Cigna thanks and I will-thank you for recognizing the power of Afrezza it is a life changer. A1c averaging 5.4 over last ten weeks
MaredinCapital (@Marcelozinn) tweeted at 8:04am - 17 Jul 15:
@Marcelozinn: Q. to #afrezza users: from time you called ur Dr, got apt, had spirometry test, how long was entire process to get Rx?
Julie (@julie007_y) tweeted at 7:27pm - 17 Jul 15:
@Marcelozinn it took about a month since insurance req prior Auth..I've been on afrezza since April. Check out @afrezzauser or
AFREZZA GUY (@Afrezzaguy) tweeted at 1:26am - 18 Jul 15:
@Marcelozinn I have @Cigna and had no issues with coverage. Sanofi rep had lung test dr all set up and ready to go after Endo appt
AFREZZA GUY (@Afrezzaguy) tweeted at 1:28am - 18 Jul 15:
@Marcelozinn most difficult part was getting Rx doses from Endo to match with Boxes Cigna had. Lung test was 20 mins in and out.
Studies have demonstrated that in-creased adherence to a treatment regi-men can reduce A1C levels,10 and many other studies have shown that A1C reductions prevent complications. A 1% reduction in A1C is associated with a 14% reduction in the risk of heart attack and a 40% reduction in the risk of eye, kidney, and nerve disease.11 (Logic says that better adherence would also slash healthcare costs, but the findings from research on that topic are mixed.10)
A number of experiments have tested different strategies for improving ad-herence to existing treatment regimens. Many have failed, but many others have produced significant gains, at least over the study period, with simple ap-proaches such as asking pharmacists to provide patients a little extra information.12 While some researchers continue to study ideas for motivating patients, others work to improve treatments.
Some people, for example, respond poorly to existing medications, so even if patients used existing options perfectly, there would still be a need for more effec-tive options. The biggest need, however, appears to be medications that promote compliance by making treatment regimens less arduous and more tolerable. Only real-world use will show if Toujeo and Afrezza meet that second need, but there are several reasons for hope.
For one, the reduction in nocturnal hy-poglycemia associated with using Toujeo rather than Lantus is reasonably large. A meta-analysis of 3 of the drug’s phase 3 trials found a 31% reduction in such reactions among 2476 patients (risk ratio, 0.69; 95% CI, 0.57-0.84; P = .0002).13
While the biggest original selling point for Lantus may have been the relatively low rate of nocturnal hypoglycemia, low blood sugar remains a serious problem. Hypoglycemia is the primary cause of roughly 282,000 emergency department visits each year,9 and many patients fear it enough to risk high blood sugar by taking less insulin than their doctors prescribe.14
Toujeo and Afrezza: New and Improved Insulins, Limited by FDA Labeling Constraints
Existing treatments are effective enough to control diabetes in most patients, but drug makers spend huge sums to keep developing new products and improving old ones.
Indeed, Sanofi just rolled out 2 novel versions of the very oldest diabetes treatment, an insulin glargine formulation called Toujeo and an inhalable form of human insulin called Afrezza.
Sanofi officials say both products will benefit large numbers of insulin users with both type 1 and type 2 diabetes mel-litus (T1DM, T2DM). Outsiders express a wide range of opinions.
Trial data indicate that Toujeo controls glycated hemoglobin (A1C) levels about as well as Lantus, an insulin glargine formulation approved in the year 2000 that has just lost patent protection after years of blockbuster sales. Toujeo lasts longer than Lantus, however.1 It also provides the body a steadier stream of insulin1 and is associated with a significantly lower risk of nocturnal hypoglycemia.1
Afrezza performed similarly in a phase 3 trial. It roughly matched an existing competitor, insulin aspart (Novolog), in A1C reduction, and slightly outperformed it in several secondary ways. Afrezza use was associated with less hypoglycemia, lower fasting blood glucose, and slight weight loss rather than slight weight gain. It also reached peak levels very quickly, in just 12 to 14 minutes on average.2
That said, Afrezza’s medical importance will likely hinge on something that no trial can measure: how the change from injection to inhalation affects patient behavior. If the delivery method inspires patients to medicate themselves more consistently, Afrezza could produce huge health benefits. If patients use Afrezza like they use insulin aspart (a fast-acting insulin analogue), the new product could prove to be an expensive convenience.
Financial analysts mostly predict solid but unspectacular sales for both drugs, in part because federal regulations for-bid Sanofi from touting the comparative advantages of either drug. (The FDA did not allow language about less hypoglycemia in the label it approved, and therefore Sanofi cannot mention it in language it uses to promote the drug.)
Consensus estimates reported by Bloomberg predict annual Toujeo sales will reach about $1.3 billion by 20203 far below the $7.1 billion that Lantus generated in 2014. As for Afrezza, annual projections range from a paltry $182 million up to $2 billion, with the median in the $600 million range. The treatment’s unexpectedly poor performance during its first month on the market led Goldman Sachs to cut its annual sales projections by $1 billion.4
In other respects, however, both medications have gotten a good reception.
“The response to Afrezza on social media has been tremendous,” Rachele Berria, MD, PhD, who heads the Diabetes Medical Unit for Sanofi US, told Evidence-Based Diabetes Management in an interview. “Healthcare providers don’t seem to anticipate that patients will see much of a need to move away from injections, but actual patients see this as a valuable feature.”
Berria says the company will study real-life Afrezza use to see if patient enthusiasm translates into patient compli-ance, and that it will follow real-world Toujeo users to measure the practical effect of its longer, steadier flow of medication. “The goal in treating diabetes is to avoid peaks and valleys in both insulin and sugar, and Toujeo does that to a degree that once seemed impossible,” she said. “There’s no insulin spike when each new injection gets absorbed, and there’s no loss of efficacy in the final few hours. It’s a big stride forward from Lantus.”
Physicians have been using insulin to treat diabetes since 1922, when Frederick Banting and Charles Best injected the hormone into a diabetic teenager at a hospital in Toronto. Eli Lilly began producing it commercially within the year, and diabetes was transformed, virtually overnight, from a speedy death sen-tence to a chronic condition.5
Intermediate acting Neutral Prot-amine Hagedorn (NPH) insulin arrived about a quarter century later, in 1950. Long-acting insulin, on the other hand, didn’t reach patients until 2000, when Lantus went on sale in the United States and Europe.
The new drug reduced A1C levels about as much as NPH insulin, but trials demonstrated that it produced a greater reduction in fasting plasma glucose and fasting blood glucose as well as a far lower risk of nocturnal hypoglycemia.6
The other big advantage of Lantus was the convenience of longer action. Patients who had spent years toting around basal insulin and setting alarms for midday injections suddenly had nothing to carry and nothing to remember except a single injection before bed. By then, of course, insulin was not the only effective treatment for T2DM. The FDA had approved metformin in 1994, and its huge success spurred drug companies to develop the other oral treatments that now crowd the market.
Many of these treatments are quite effective, especially when used in combination. Indeed, if used properly, their excellent disease control could greatly reduce diabetic complications and the need for new drugs.
Yet pharmaceutical companies continue developing treatments like Toujeo and Afrezza because a huge percentage of diabetics fail to control their condition with current options. A recent study that examined records from more than 43,000 patients found that less than 55% of all Americans who have been diagnosed with diabetes, and prescribed medication to control blood sugar, actually man-age to keep their A1C level under 7%.7
The main cause of this problem seems to be patient behavior. Studies have found that patient adherence to oral treatment protocols can range from more than 90% down to just over 50%. Strict adherence to guidelines concerning injectable medications and proper diet tends to be lower, while strict ad-herence to guidelines concerning mod-erate, regular exercise and blood sugar checks is downright rare.8 The chance that any patient will adhere perfectly to a complex regimen is low, and studies of people with all types of chronic disease have typically found that only about half of them will make a serious effort to manage their condition.8
The consequences of this behavior are dire.Diabetes is the nation’s seventh-lead-ing cause of death. It increases the risk of stroke (by 50%), heart attack (by 80%), and death from cardiovascular disease (by 70%). It is also the leading cause of kidney failure and non-traumatic lower limb amputation. The American Diabetes Association estimates that the di-rect medical cost of treating diabetes reached $176 billion in 2012, and indi-rect costs such as lost productivity add-ed another $69 billion to the tally.
David Kliff: @nickcullinane never said #afrezza doesn't work as a therapy this isn't about whether it works or not
7:32am - 17 Jul 15